Bausch & Lomb ZyLET "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bausch & Lomb continues to expect a second-half 2004 approval of ZyLET (loteprednol etabonate 0.5%/tobramycin 0.3%) following a July "approvable" letter. The ophthalmic combination product "is aimed at treating patients with steroid-responsive inflammatory ocular conditions who have or are at risk of developing superficial bacterial ocular infections," former marketing partner Pharmos said. The ZyLET NDA was submitted in September 2003...
You may also be interested in...
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.